Impaired immune responsiveness is a significant barrier to vaccination of neonates. By way of example, the low seroconversion observed following influenza vaccination has led to restriction of its use to infants over 6 months of age, leaving younger infants vulnerable to infection. Our previous studies using a non-human primate neonate model demonstrated that the immune response elicited following vaccination with inactivated influenza virus could be robustly increased by inclusion of the Toll-like receptor agonist flagellin or R848, either delivered individually or in combination. When delivered individually, R848 was found to be the more effective of the two. To gain insights into the mechanism through which these adjuvants functioned in vivo, we assessed the initiation of the immune response, i.e. at 24 hr, in the draining lymph node of neonate non-human primates. Significant up-regulation of co-stimulatory molecules on dendritic cells could be detected, but only when both adjuvants were present. In contrast, R848 alone could increase the number of cells in the lymph node, presumably through enhanced recruitment, as well as B-cell activation at this early time-point. These changes were not observed with flagellin and the dual adjuvanted vaccine did not promote increases beyond those observed with R848 alone. In vitro studies showed that R848 could promote B-cell activation, supporting a model wherein a direct effect on neonate B-cell activation is an important component of the in vivo potency of R848 in neonates.
Introduction
The impaired immune response in infants makes the development of effective vaccine strategies particularly challenging. Achieving protective levels of immunity is hampered by IgG antibody responses that are reduced in both level and affinity through the first year of life. 1, 2 In human neonates there is evidence supporting a generalized defect in T-cell responsiveness, [2] [3] [4] [5] [6] [7] [8] which may hinder antibody production as a result of a compromised CD4 + response. Finally, neonates appear to have a heightened regulatory T-cell response, 9, 10 adding another barrier to the generation of an adaptive immune response. Vaccines that can work effectively in neonates must be capable of overcoming these appreciable obstacles.
Significant effort has been expended in harnessing the power of Toll-like receptor (TLR) agonists to improve vaccines with promising results (for review see ref. 11 ). We and others have begun to explore this as a mechanism to overcome the immune deficits present in neonates. [12] [13] [14] [15] TLRs belong to a family of receptors that recognize molecules derived from viral, bacterial and fungal pathogens as Abbreviations: AGM, African green monkey; AxLN, axillary lymph node; DCs, dendritic cells; flg, flagellin; NHP, non-human primate; TLR, Toll-like receptor
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well as endogenous molecules that signal danger. 16, 17 This family of receptors is broadly distributed on innate and adaptive immune cells and as a result multiple cell types including T cells, B cells and dendritic cells (DCs) can be modulated by these ligands. The representation of individual receptors differs with cell type and, hence, the choice of ligand will determine the population activated.
A critical target for generation of an adaptive immune response is DCs, as these cells play a central role in the generation of immunity as initiators of T-cell activation. Results from DCs generated from human cord blood reveal that these cells are capable of responding to TLR engagement, although they are impaired compared with cells derived from adults. [18] [19] [20] [21] [22] [23] Of note, these studies were performed with in vitro differentiated cells, which are thought to resemble dermal-like CD1a + conventional DCs 24 and therefore may not reflect other subsets. Not surprisingly, there is a paucity of data from in vivo differentiated human neonate DCs. The suboptimal responsiveness reported in neonate DCs is manifest as a decrease in the expression of co-stimulatory molecules and a reduction in interleukin-12 (IL-12). These findings led us to hypothesize that enhancing DC maturation through increasing the strength of signalling through TLR would promote greater activation of T cells following vaccination. In addition, the ability of TLR agonists to act directly on T or B cells would further facilitate immune activation.
We chose two TLR agonists, the TLR5 ligand flagellin and the TLR7/8 ligand R848, for assessment as effective adjuvants in the context of neonate vaccination. R848 (or its closely related analogue 3M-012) has shown promise in adult models of vaccination. [25] [26] [27] [28] It is reported to increase cell-mediated immune responses when incorporated into hepatitis B surface antigen (HBsAg) 25 or HIV gag 26 protein vaccines. Further, R848 can induce robust antibody production. 27, 28 Increased antibody production may occur through indirect effects of R848 on CD4 + T cells or directly through its ability to activate B cells. [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] The capacity for R848 to signal through TLR8 in addition to TLR7 is an attractive attribute given reports that TLR8 agonists suppress regulatory T cells 39 in addition to inducing robust T helper type 1-biasing cytokines in neonatal antigenpresenting cells. 40 Hence, R848 has the potential to overcome two obstacles associated with neonates, T helper type 2 skewing and increased regulatory T cells.
The other agonist we explored, flagellin (flg), is also a potent adjuvant for the induction of antibody responses (for review see refs 41, 42) . The potency of flagellin as an adjuvant is in part due to its ability to induce activation of DCs. 43 In addition, TLR5 agonists have the potential to act directly on primate T cells, promoting increases in both proliferation and cytokine production. 41, [44] [45] [46] Importantly, there are data supporting the effectiveness of this molecule for activation of T cells from neonates. 44 Finally, flagellin effectively recruits T and B cells to secondary lymphoid sites, promoting more efficient activation of relevant immune effectors. 45, 47, 48 Hence, this adjuvant has the capacity to facilitate the generation of an immune response through its action on multiple cell types.
In our studies we have used a non-human primate (NHP) model to assess the potential for flagellin or R848 to serve as effective activators of the immune system in the context of neonate vaccination against influenza. [12] [13] [14] We developed an R848-adjuvanted vaccine wherein R848 was directly conjugated to the influenza virion. We chose this approach because of the growing number of reports showing that direct conjugation of a TLR agonist to an antigen improves responses following vaccination (for review see ref. 49 ). Vaccination of neonate NHP resulted in improved immune responses when either flagellin or R848 were included as adjuvants, 13, 14 although R848 was superior to flagellin. The goal of the studies reported here was to understand at a mechanistic level how these adjuvants were working to enhance immunity in the context of the neonate. To address this critical question, we isolated the draining lymph nodes from vaccinated NHP neonates at 24 hr post vaccination. Antigen-presenting cell number and maturation were assessed, as were the number and activation of T-cell and B-cell populations. Our results support a direct effect on B cells as a component of the improved in vivo activity of R848.
Materials and methods

Vaccination
African green monkey (AGM) infants (Caribbean-origin Chlorocebus aethiops sabaeus) used in this study were housed at the Vervet Research Colony at Wake Forest School of Medicine. At 3-5 days of age, infants were vaccinated intramuscularly with 45 lg of 0Á74% formaldehyde-inactivated A/Puerto Rico/8/1934 [H1N1] (PR8) virus mixed with 10 lg of flagellin (flg) or a biologically inactive hypervariable region construct (m229) 47, 50 or inactivated PR8 conjugated with R848 (IPR8-R848). Flagellin and IPR8-R848 were also co-administered. Control animals received PBS. For the IPR8-R848 conjugate vaccine, 13 an amine derivative of R848 (hereon referred to as R848) was linked to SM(PEG) 4 (Thermo Scientific, Waltham, MA) by incubation in DMSO for 24 hr at 37°. R848-SM(PEG) 4 was then incubated with influenza virus that had been reduced to generate free thiol groups (IPR8-R848). Unconjugated R848 was removed by extensive dialysis. This construct was then inactivated by treatment with 0Á74% formaldehyde for 1 hr at 37°, followed by dialysis. Successful conjugation was assessed by differential stimulation of RAW264.7 cells (Wake Forest Comprehensive Cancer Center Cell and Viral Vector Core Laboratory) following incubation with similar doses (based on protein content) of R848-conjugated versus non-conjugated vaccine. Flagellin from Salmonella enteritidis was prepared as previously described. 50 Endotoxin 
Cytokine production by RT-PCR in AxLN cells
Total RNA was isolated from pelleted AxLN cells using an RNeasy Plus Mini Kit (Qiagen, Hilden, Germany). cDNA was synthesized using SuperScript III First Strand Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA). Quantitative PCR was performed with a TaqMan PCR system (Applied Biosystems, Foster City, CA). The TaqMan primers and probes used are as follows: IL-10 forward (TTGCTGGAGGACTTTAAGGGTTAC), reverse (TCAGC TTGGGGCATAACC) and probe (TTGCCAAGCCTTGTC TGAGATGATCCA); tumour necrosis factor-a forward (ATGGCAGAGAGGAGGTTGACC), reverse (TACTCCCA GGTCCTCTTCA), and probe (CAGCCGCATCGCCGTC TCCT); interferon-b forward (GCCTCAAGGACAGGATG AACTT), reverse (CGTCCTCCTTCTGGAACTGC), and probe (CATCCCTGAGGAAATTAAGCAGCCGC); CXCL10 forward (CCAAGTCAATTTTGTCCACATGTT), reverse (CAGACACCTCTTCTCACCCTTCTT), and probe (AGAT CATTGCTACAATGAA); IL-6 forward (TGCTTTCACAC ATGTTACTCCTGTT), reverse (CATCCTCGACGGCATC TCA), and probe (ATGTCTCCTTTCTCAGGGC); and b-actin forward (GCTGCCCTGAGGCTCTCTT), reverse (TGATGGAGTTGAAGGTAGTTTCATG), and probe (TT CCTGGGCATGGAGT). The TaqMan probe for IL-12B was from Applied Biosystems. b-Actin was used to normalize gene expression across samples.
Analysis of splenic B-cell activation by TLR ligands
Spleens were isolated from four newborn AGM (4-5 days of age) at necropsy. Single-cell suspensions were prepared from mechanically dispersed tissue and frozen for future study. Cells were thawed by placement in a 37°water bath for 10 min. This was followed by slow dilution with warm medium containing DNase I (0Á1 mg/ml, StemCell Technologies, Vancouver, Canada). Recovered cells were > 90% viable. B cells were enriched using Miltenyi CD20-conjugated microbeads as per the manufacturer's instructions with the modification of doubling the amount of beads due to the very high percentage of B cells present in the spleen. Then, 5 9 10 5 isolated cells were cultured in round-bottom plates for 24 hr in the presence of the amine derivative of R848 used in our vaccination study (5 or 25 lg/ml), flagellin (100 or 500 nM), or the combination of the two adjuvants (5 lg/ml R848 + 100 nM flagellin or 25 lg/ml R848 + 500 nM flagellin). B-cell activation was assessed by measuring CD86 expression.
Statistical analysis
Significance was determined by a one-way analysis of variance test using GRAPHPAD PRISM software (GraphPad, San Diego, CA.
Results
IPR8-conjugated R848 results in an increase in the number of cells in the draining LN at 24 hr following vaccination
To determine the effect of the TLR agonists R848 and flagellin on the immune response following vaccination with inactivated influenza virus (IPR8), newborn AGM (3-5 days old) were vaccinated in the right arm with inactivated PR8 together with flagellin (IPR8 + flg), IPR8 conjugated to R848 (IPR8-R848), IPR8 conjugated to R848 plus flagellin (IPR8-R848 + flg), or IPR8 plus the inactive flagellin protein m229 (IPR8 + m229). The lack of stimulatory activity of m229 was demonstrated by the failure to increase CD40 on THP-1 cells or tumour necrosis factor-a production in RAW264.7 cells (Fig. S1 ). All newborn animals received PBS injections in the left arm. Twenty-four hours post vaccination, the left and right AxLN were isolated by biopsy and cells were isolated by dissociation in the presence of collagenase D.
No differences were observed in the total number of cells obtained from AxLN of newborns vaccinated with IPR8 + m229 or IPR8 + flg compared with newborns that received PBS (Fig. 1) . However, the AxLN isolated from newborns that received an R848-conjugated vaccine (IPR8-R848 or IPR8-R848 + flg) had a significantly higher number of cells compared with non-vaccinated animals. Increased recruitment was restricted to the LN draining the vaccine site (vaccine) and was not observed in the axillary node draining the PBS injection site (Fig. 1 ).
R848-containing vaccines fail to promote an increase in DC and macrophages in the draining LN at 24 hr post vaccination
Initiation of a T-cell response is dependent on presentation by professional APC, most often DC. However, macrophages may also serve in this capacity under some circumstances. 51 Hence, we determined how the presence of the adjuvants impacted the recruitment of DCs and macrophages to the LN. Dendritic cells were identified by the expression of CD11c and macrophages by positive staining for CD11b and CD14. Representative plots and gating strategy are shown in Fig. 2(a) . None of the adjuvanted vaccines resulted in a significant increase in the number of DCs or macrophages compared with the nonadjuvanted vaccine IPR8 + m229 or non-vaccinated newborns (Fig. 2b,c) . As would be expected, there were no differences in the numbers of cells in the LN draining the PBS injection site (see Supplemetary material, Fig. S2 ).
The combination of R848 and flagellin results in increased maturation of DCs in the draining LN at 24 hr post vaccination
We next examined whether the presence of the adjuvants impacted the maturation of DCs and macrophages, as measured by the level of CD80 and CD86. Data showing the level of CD80 and CD86 on DCs and macrophages from individual animals is shown in Fig. 3 . The presence of either R848 or flagellin alone had minimal effects on the expression of CD80 and CD86 on DCs. Only DCs from newborns vaccinated with the dual-adjuvanted vaccine (IPR8-R848 + flg) exhibited significantly higher levels of these two markers at the population level (Fig. 3a,b) . These data show that adjuvanting with either flagellin or R848 alone did not induce significant increases in DC maturation. This is in contrast to the maturation observed when both adjuvants were included in the vaccine.
The expression of CD80 and CD86 on macrophages exhibited a different pattern. The presence of flagellin was unexpectedly associated with reduced expression of these markers compared with those receiving the R848-adjuvanted vaccine (Fig. 3c,d) . Although not significant, as shown above (Fig. 2) , there was a trend towards an increase in macrophages following vaccination with IPR8 + flg. It is therefore tempting to speculate that flagellin delivered alone may recruit macrophages that have lower expression of CD80 and CD86 to the AxLN.
Analysis of cytokine mRNA levels in the AxLN following vaccination
Given the lack of association of DC maturation or number with the increased immune response in neonates The presence of conjugated R848 results in an increase in the number of cells in the draining lymph node. Neonate African green monkeys were injected intramuscularly in the right arm with IPR8 + m229, IPR8 + flg, IPR8-R848, IPR8-R848 + flg, or PBS. All infants received PBS in the left arm. Twenty-four hours later, draining axillary lymph nodes were isolated, mechanically dissociated, incubated with collagenase D, and subsequently quantified. Each group contained five animals. Cell numbers (average AE SEM) in vaccinated neonates were compared with neonates that received PBS. Significance was determined using a two-way analysis of variance. *P < 0Á05, **P < 0Á005. observed following vaccination with IPR8-R848 or IPR8 + flg vaccines, 13, 14 we tested the hypothesis that the cytokine milieu differed following delivery of the adjuvants. levles of mRNA for the pro-inflammatory cytokines tumour necrosis factor-a, IL-6 and CXCL10 were measured in the AxLN of the vaccinated newborns. We also assessed IL-12b and interferon-b given their reported role in T helper type 1 differentiation and/or acquisition of effector function in CD8 + T cells. 52, 53 Finally, we determined whether there were changes in the antiinflammatory cytokine IL-10, which has been reported to be over-expressed in infant DCs. 22 No consistent adjuvant-associated increase in any of the assessed pro-inflammatory cytokines was observed (Fig. 4) . There was a trend towards a decrease in IL-10 in newborns receiving the adjuvanted vaccines compared with newborns that received IPR8 + m229, although this did not meet statistical significance. 
Analysis of T-cell activation as a result of vaccination
The lack of increased antigen-presenting cell maturation or number when R848 or flagellin alone was included in the vaccine was surprising given the potent effects of the adjuvants on adaptive immune responses observed in vivo in our previous studies. 13, 14 In view of the expression of TLR5 and TLR7/8 on T cells, [29] [30] [31] we asked whether there was evidence of increased recruitment or direct activation of T cells that was associated with the presence of the adjuvants. We first assessed the number of CD4 + and CD8 + T cells in the draining AxLN at 24 hr post vaccination. The presence of activated cells was measured by CD69 expression. There was no significant increase in the total number of CD8 + or CD4 + T cells or the number of activated CD8 + T cells in any of the vaccinated groups, although there was a trend towards an increased number of activated CD8 + cells in the presence of adjuvant (Fig. 5, upper panels) . As would be expected, there was also no significant increase in the number of these cells in the LN draining the PBS injection site (see Supplementary material, Fig. S3 ).
Although the adjuvants did not impact the number of CD4 + T cells found in newborns, there was a significant increase in CD69 + CD4 + cells in the draining LN of the dual-adjuvanted vaccine compared with both PBSvaccinated and IPR8 + m229-vaccinated animals (Fig. 5 , bottom panels). Vaccination with IPR8-R848 + flg induced a 3Á7-fold increase compared with the PBS group and a 2Á3-fold increase compared with the IPR8 + m229 group. No other vaccine resulted in a significant increase in cell number. Hence, as with DC maturation, the combined presence of the adjuvants resulted in the most robust activation of T cells at 24 hr post-vaccination, although this was restricted to the CD4 + subset.
Increased B-cell activation is associated with vaccines containing conjugated R848
We next evaluated B cells in the draining LN at 24 hr post vaccination. There was no significant increase in CD20 + cells in the AxLN of newborns vaccinated with IPR8 + m229 or IPR8 + flg compared with PBS controls (Fig. 6a) . In contrast, the number of CD20 + cells was significantly increased in newborns that received IPR8-R848 (5Á5-fold) or IPR8-R848 + flg (5Á3-fold) compared with PBS. The number was also significantly increased when compared with IPR8 + flg vaccinated newborns (IPR8-R848 increased 3Á5-fold and IPR8-R848 + flg increased 3Á3-fold (Fig. 6a) . When activated B cells were assessed, we saw a corresponding significant increase (7Á1-fold) in CD69 + CD20 + cells in newborns vaccinated with IPR8-R848 compared with animals that received IPR8 + flg (Fig. 6b) . As with CD20 + cell number, there was no further increase in newborns that received both flagellin and R848 (Fig. 6b) . These increases were restricted to the vaccine draining LN as no significant difference in B cells (total or CD69 + ) was observed in the LN draining the PBS injection site of animals vaccinated with IPR8-R848 or IPR8-R848 + flg (see Supplementary material, Fig. S3 ). These data support the potential for R848 to directly activate B cells in the newborns.
To test this hypothesis we isolated splenic B cells from four newborn AGM (4-5 days old) by positive selection with CD20 + microbeads. This approach resulted in populations that were ≥ 95% CD20 + (data not shown). B-cell populations were stimulated for 24 hr with 5 lg/ml R848 and 100 nM flagellin, concentrations within the range of those previously reported to be stimulatory. 32, 43 Flagellin did not significantly increase the percentage of cells that stained positive for CD69 (Fig. 7a) . However, B cells from neonates cultured in the presence of R848 exhibited robust and significant increases in CD69 + cells compared with unstimulated cultures (Fig. 7a) . We also evaluated CD86 expression as an indicator of activation. Surprisingly, we observed no increase in the expression of this molecule with any of the conditions tested (Fig. 7b) . To determine whether R848 could induce up-regulation of CD86 on neonate B cells, the concentration of each agonist was increased fivefold. The higher amount of flagellin still failed to increase CD86 expression. Of note, the flagellin was active as it induced up-regulation of CD86 on NHP DCs (data not shown). However, in stark contrast to flagellin, the higher concentration of R848 induced robust up-regulation of CD86, with 93% of the cells exhibiting positivity (Fig. 7c) . This result supports the potential for R848 engagement of TLR7/8 on B cells to promote B-cell activation in neonates and is therefore a likely contributor to the high level of antibody detected in our newborn NHP model. 13, 14 .
Discussion
This study sought to understand how the presence of the TLR agonist flagellin or R848 impacted the early response in the draining LN of neonate NHP following vaccination with inactivated influenza virus. This analysis was prompted by our in vivo studies showing that these adjuvants could increase the antibody and T-cell responses elicited by vaccination with IPR8. [12] [13] [14] Although each of the adjuvants promoted an increased response in vivo, conjugated R848 was the more effective of the two, while at the same time having reduced systemic inflammation.
13,14 Surprisingly, we found that neither flagellin nor R848 had a detectable effect on DC number or function, although we did observe a significant increase in DC maturation when the adjuvants were co-delivered. It was surprising that we failed to detect a significant increase in CD80/CD86 on DCs or cytokine production in neonates that received the singly adjuvanted vaccine. We had expected to see this effect given the increase in T-cell and antibody responses detected in neonates that received these vaccines. 13, 14 We acknowledge that using an NHP model limits the number of time-points that can be examined and that the single adjuvant vaccines may have additional changes at a later time-point. We chose 24 hr based on studies in mouse and NHP models where antigen could be detected at day 1 in the draining LN following administration at a distal site. [54] [55] [56] [57] [58] With that said, adjuvants can induce detectable changes in co-stimulatory molecules at this time as evidenced by the increases observed following co-delivery of R848 and flagellin. In addition, our CD69 data support the presence of the vaccine antigen/adjuvants in the draining LN at this time. However, it remains possible that the single adjuvants are delayed in maturation. It is also possible that R848 or flagellin alone may result in maturation of a small subset of DCs that is below our detection limit in the readout. In contrast, analysis of B cells in the draining LN showed that inclusion of R848 was associated with a significant increase in recruitment and activation at early times, e.g. at 24 hr, following vaccination. In vitro studies confirmed 62 There is evidence that TLR stimulation on B cells can contribute directly to antibody responses generated in the context of virus infection 63, 64 as well as vaccines. 65, 66 With regard to the latter, in a study using adult lMT mice reconstituted with MyD88-sufficient or -deficient B-cell populations, Kasturi et al. 65 showed that TLR signalling on B cells was an important component of optimal antibody responses following vaccination with a model antigen (ovalbumin) nanoparticle vaccine. Further, in a recent study from Onodera et al., 66 an inactivated whole influenza virion vaccine was found to accelerate the recall antibody response to vaccination compared with a split-virion vaccine. Follow-up studies revealed that this was the result of an early TLR7-dependent activation of memory B cells. These results are in agreement with the R848-mediated activation observed here. As human B cells express TLR7, [32] [33] [34] [35] [36] we would expect a similar effect in human infants administered R848-containing vaccines. In our studies, flagellin failed to activate naive B cells. This is likely the result of an absence of TLR5 on naive NHP B cells, similar to what has been reported in mice and humans. 33, 67, 68 The agreement between human and NHP TLR distribution/function, i.e. the failure of flagellin to activate neonate B cells coupled with the stimulatory capacity of R848, observed in our study provides continued support for the use of the NHP neonate model for TLR adjuvant testing.
Given the known ability of TLR to promote B-cell activation in adults, Pettengill et al. assessed TLR expression in cord-blood-derived B cells. They found that many of the TLR, including TLR7, were expressed at levels similar to those in adult cells. 36 Further, cord blood B cells responded to R848 stimulation by production of cytokines and up-regulation of co-stimulatory molecules, + cells were stimulated with 25 lg/ml R848, 500 nM flagellin, or the combination for 24 hr and assessed for the expression of CD86. **P < 0Á005, ***P < 0Á0005, ****P < 0Á0001. although certainly some of these responses were diminished compared with adult cells. 36 The data presented here add further evidence for the ability of R848 to promote neonate B-cell activation and suggest that this is an important contributor to the in vivo adjuvant function of R848 in this population.
CD69 is known to promote retention of lymphocytes in the LN through its binding to S1P 1 , promoting its internalization and thereby inhibiting lymphocyte egress.
69 R848-mediated increases in CD69 early in the immune response may facilitate B-cell retention in the LN, thereby promoting differentiation, consistent with our data showing an increase in B-cell number following vaccination with R848-containing vaccines. It is important to keep in mind that the R848 in our vaccine construct is conjugated to the virus particle. This should target the enhancing effects of R848 primarily to virusspecific cells as access to endosomal TLR7 in the B cells by IPR8-R848 requires uptake. 35 In summary, we show here that inclusion of adjuvants in an inactivated influenza virus vaccine administered to neonate NHP results in immune activation in the draining LN at 24 hr. The potent signal delivered by the combination of two TLR agonists, flagellin and R848, resulted in significant up-regulation of co-stimulatory molecules on DCs, whereas delivery of either of the adjuvants alone did not. The in vivo efficacy of R848 was associated with an increase in B-cell activation observed at early times following vaccination, i.e. 24 hr. In vitro studies confirmed the ability of R848 to directly promote B-cell activation. Hence, direct effects on neonate B cells may be an important attribute of the potency of R848 previously observed in vivo in this model.
Supporting Information
Additional Supporting Information may be found in the online version of this article: Figure S1 . m229 does not have stimulatory activity. Figure S2 . There are no significant differences in the number of CD11c + or CD14 + CD11b + cells in the draining axillary lymph nodes of the PBS control arm of the vaccinated compared to non-vaccinated (PBS) animals. Figure S3 . The number of total or activated T or B cells in the draining axillary lymph nodes of the PBS control arm of the vaccinated newborns is not significantly different from the number in the animals that did not receive vaccine (PBS).
